ARIAD Pharmaceuticals completes rolling submission of ponatinib NDA with FDA ARIAD Pharmaceuticals.

ARIAD offered the FDA with remaining chemistry, manufacturing, and controls data. ARIAD is searching for U.S. Marketing approval of ponatinib in sufferers with resistant or intolerant chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia . The ongoing firm has requested accelerated authorization and a priority review of the ponatinib application by the FDA. Paul Liu called 2015 Distinguished Alumnus for contributions to leukemia researchYK-4-279 compound works against some types of leukemia: StudyTargeting exhausted immune cells may transformation prognosis for leukemia relapse individuals after transplant’In past due July, we submitted the NDA for ponatinib ahead of schedule and, at the request of the FDA, in advance of having the last CMC data.Although no major safety issues possess arisen in infants or moms taking this therapy, the emergence of drug resistance has created a growing problem to the scientific and community health communities., a subsidiary of Eisai Inc., announced today that The American Association of Pharmaceutical Researchers provides awarded its 2012 Excellence in Ligand Binding Assays Award to the Bioanalytical Development group from Morphotek because of their abstract, Advancement and Validation of a Pharmacokinetic Assay on the Gyrolab Platform for Use in Stage II/III Clinical Studies. The award was offered at the AAPS 2012 National Biotechnology Meeting held May 21-23 in NORTH PARK.